TORONTO, March 02, 2021 (GLOBE NEWSWIRE) — Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), who through its wholly-owned subsidiary, PharmaTher Inc. (“PharmaTher”), is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce that PharmaTher has entered into an exclusive license agreement with The University of Kansas…

Source

Previous articleCOMPASS Pathways plc to announce fourth quarter and full year 2020 financial results on 9 March 2021
Next articleNeonMind Files Four Additional Provisional Patents on Psilocybin Preclinical Data